tiprankstipranks
Regeneron Pharmaceuticals (DE:RGO)
NASDAQ:RGO
Germany Market
RGO
Regeneron
RESEARCH TOOLSreports

Regeneron (RGO) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

RGO Analyst Ratings

Moderate Buy
21Ratings
Moderate Buy
15 Buy
6 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Regeneron
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RGO Stock 12 Month Forecast

Average Price Target

€712.05
▲(12.35% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is €712.05 with a high forecast of €856.79 and a low forecast of €551.96. The average price target represents a 12.35% change from the last price of €633.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"430":"€430","857":"€857","536.75":"€536.8","643.5":"€643.5","750.25":"€750.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":856.79251,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€856.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":712.0460366666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€712.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":551.9638180000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€551.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[430,536.75,643.5,750.25,857],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,519,544.9840392307692,570.9680784615384,596.9521176923076,622.936156923077,648.9201961538462,674.9042353846154,700.8882746153846,726.8723138461538,752.8563530769231,778.8403923076924,804.8244315384616,830.8084707692308,{"y":856.79251,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,519,533.8496951282051,548.6993902564103,563.5490853846154,578.3987805128205,593.2484756410256,608.0981707692308,622.9478658974359,637.797561025641,652.6472561538462,667.4969512820513,682.3466464102564,697.1963415384616,{"y":712.0460366666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,519,521.5356783076924,524.0713566153846,526.607034923077,529.1427132307692,531.6783915384616,534.2140698461538,536.7497481538462,539.2854264615385,541.8211047692308,544.3567830769231,546.8924613846154,549.4281396923077,{"y":551.9638180000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":431.712,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":439.867,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":467.415,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.013,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":521.121,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":566.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":653.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":659.991,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":637.852,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":669.369,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":667.571,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":573.916,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":519,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€856.79Average Price Target€712.05Lowest Price Target€551.96
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:RGO
Biren Amin
Piper Sandler
Piper Sandler
€736.24
Buy
16.16%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), Vera Therapeutics (NASDAQ: VERA) and Regeneron (NASDAQ: REGN)
BMO Capital Analyst forecast on DE:RGO
Evan Seigerman
BMO Capital
BMO Capital
€628.6
Buy
-0.82%
Downside
Reiterated
05/21/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)
Scotiabank Analyst forecast on DE:RGO
Louise Chen
Scotiabank
Scotiabank
€663.05
Hold
4.61%
Upside
Reiterated
05/19/26
Scotiabank Sticks to Its Hold Rating for Regeneron (REGN)
Canaccord Genuity Analyst forecast on DE:RGO
John Newman
Canaccord Genuity
Canaccord Genuity
€910.18→€753.46
Buy
18.88%
Upside
Reiterated
05/19/26
Regeneron price target lowered to $875 from $1,057 at CanaccordRegeneron price target lowered to $875 from $1,057 at Canaccord
Leerink Partners Analyst forecast on DE:RGO
David Risinger
Leerink Partners
Leerink Partners
€681.99→€551.96
Hold
-12.91%
Downside
Downgraded
05/18/26
Regeneron downgraded to Market Perform from Outperform at LeerinkRegeneron downgraded to Market Perform from Outperform at Leerink
Evercore ISI Analyst forecast on DE:RGO
Cory Kasimov
Evercore ISI
Evercore ISI
€753.46→€710.41
Buy
12.09%
Upside
Reiterated
05/18/26
Regeneron price target lowered to $825 from $875 at Evercore ISIRegeneron price target lowered to $825 from $875 at Evercore ISI
Truist Financial Analyst forecast on DE:RGO
Gregory Renza
Truist Financial
Truist Financial
€685.43→€669.93
Buy
5.70%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Tonix Pharma (NASDAQ: TNXP) and Regeneron (NASDAQ: REGN)
Citi Analyst forecast on DE:RGO
Geoff Meacham
Citi
Citi
€774.99→€602.77
Hold
-4.90%
Downside
Downgraded
05/18/26
Citi downgrades Regeneron (REGN) to a Hold
Wells Fargo Analyst forecast on DE:RGO
Mohit Bansal
Wells Fargo
Wells Fargo
€688.88→€602.77
Hold
-4.90%
Downside
Assigned
05/18/26
Wells Fargo Gives a Hold Rating to Regeneron (REGN)
Goldman Sachs Analyst forecast on DE:RGO
Salveen Richter
Goldman Sachs
Goldman Sachs
€833.54
Buy
31.52%
Upside
Reiterated
05/18/26
Regeneron: Buy Rating and $968 Price Target Reaffirmed Despite Fi Anlimab Setback, Backed by Robust Pipeline and IP Extensions
J.P. Morgan Analyst forecast on DE:RGO
Chris Schott
J.P. Morgan
J.P. Morgan
€818.04→€731.93
Buy
15.48%
Upside
Assigned
05/18/26
Regeneron price target lowered to $850 from $950 at JPMorganRegeneron price target lowered to $850 from $950 at JPMorgan
Barclays Analyst forecast on DE:RGO
Eliana Merle
Barclays
Barclays
€789.63
Buy
24.59%
Upside
Reiterated
05/18/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Korro Bio (KRRO)
Wolfe Research Analyst forecast on DE:RGO
Alexandria Hammond
Wolfe Research
Wolfe Research
€740.54
Buy
16.84%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Regeneron (NASDAQ: REGN)
RBC Capital Analyst forecast on DE:RGO
Brian Abrahams
RBC Capital
RBC Capital
€656.16→€608.8
Hold
-3.95%
Downside
Reiterated
05/17/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Regeneron (NASDAQ: REGN) and Corvus Pharmaceuticals (NASDAQ: CRVS)
Bank of America Securities Analyst forecast on DE:RGO
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€740.54
Buy
16.84%
Upside
Reiterated
05/17/26
Regeneron Buy Rating Reiterated as Analyst Keeps $860 Price Target After LAG-3 Setback
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:RGO
Biren Amin
Piper Sandler
Piper Sandler
€736.24
Buy
16.16%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), Vera Therapeutics (NASDAQ: VERA) and Regeneron (NASDAQ: REGN)
BMO Capital Analyst forecast on DE:RGO
Evan Seigerman
BMO Capital
BMO Capital
€628.6
Buy
-0.82%
Downside
Reiterated
05/21/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)
Scotiabank Analyst forecast on DE:RGO
Louise Chen
Scotiabank
Scotiabank
€663.05
Hold
4.61%
Upside
Reiterated
05/19/26
Scotiabank Sticks to Its Hold Rating for Regeneron (REGN)
Canaccord Genuity Analyst forecast on DE:RGO
John Newman
Canaccord Genuity
Canaccord Genuity
€910.18→€753.46
Buy
18.88%
Upside
Reiterated
05/19/26
Regeneron price target lowered to $875 from $1,057 at CanaccordRegeneron price target lowered to $875 from $1,057 at Canaccord
Leerink Partners Analyst forecast on DE:RGO
David Risinger
Leerink Partners
Leerink Partners
€681.99→€551.96
Hold
-12.91%
Downside
Downgraded
05/18/26
Regeneron downgraded to Market Perform from Outperform at LeerinkRegeneron downgraded to Market Perform from Outperform at Leerink
Evercore ISI Analyst forecast on DE:RGO
Cory Kasimov
Evercore ISI
Evercore ISI
€753.46→€710.41
Buy
12.09%
Upside
Reiterated
05/18/26
Regeneron price target lowered to $825 from $875 at Evercore ISIRegeneron price target lowered to $825 from $875 at Evercore ISI
Truist Financial Analyst forecast on DE:RGO
Gregory Renza
Truist Financial
Truist Financial
€685.43→€669.93
Buy
5.70%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Tonix Pharma (NASDAQ: TNXP) and Regeneron (NASDAQ: REGN)
Citi Analyst forecast on DE:RGO
Geoff Meacham
Citi
Citi
€774.99→€602.77
Hold
-4.90%
Downside
Downgraded
05/18/26
Citi downgrades Regeneron (REGN) to a Hold
Wells Fargo Analyst forecast on DE:RGO
Mohit Bansal
Wells Fargo
Wells Fargo
€688.88→€602.77
Hold
-4.90%
Downside
Assigned
05/18/26
Wells Fargo Gives a Hold Rating to Regeneron (REGN)
Goldman Sachs Analyst forecast on DE:RGO
Salveen Richter
Goldman Sachs
Goldman Sachs
€833.54
Buy
31.52%
Upside
Reiterated
05/18/26
Regeneron: Buy Rating and $968 Price Target Reaffirmed Despite Fi Anlimab Setback, Backed by Robust Pipeline and IP Extensions
J.P. Morgan Analyst forecast on DE:RGO
Chris Schott
J.P. Morgan
J.P. Morgan
€818.04→€731.93
Buy
15.48%
Upside
Assigned
05/18/26
Regeneron price target lowered to $850 from $950 at JPMorganRegeneron price target lowered to $850 from $950 at JPMorgan
Barclays Analyst forecast on DE:RGO
Eliana Merle
Barclays
Barclays
€789.63
Buy
24.59%
Upside
Reiterated
05/18/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Korro Bio (KRRO)
Wolfe Research Analyst forecast on DE:RGO
Alexandria Hammond
Wolfe Research
Wolfe Research
€740.54
Buy
16.84%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Regeneron (NASDAQ: REGN)
RBC Capital Analyst forecast on DE:RGO
Brian Abrahams
RBC Capital
RBC Capital
€656.16→€608.8
Hold
-3.95%
Downside
Reiterated
05/17/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Regeneron (NASDAQ: REGN) and Corvus Pharmaceuticals (NASDAQ: CRVS)
Bank of America Securities Analyst forecast on DE:RGO
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€740.54
Buy
16.84%
Upside
Reiterated
05/17/26
Regeneron Buy Rating Reiterated as Analyst Keeps $860 Price Target After LAG-3 Setback
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months
Yatin SunejaGuggenheim
Success Rate
9/14 ratings generated profit
64%
Average Return
+2.62%
Copying Yatin Suneja's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +2.62% per trade.
1 Year
Yatin SunejaGuggenheim
Success Rate
10/14 ratings generated profit
71%
Average Return
+15.74%
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +15.74% per trade.
2 Years
Christopher RaymondRaymond James
Success Rate
19/39 ratings generated profit
49%
Average Return
+6.54%
Copying Christopher Raymond's trades and holding each position for 2 Years would result in 48.72% of your transactions generating a profit, with an average return of +6.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGO Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
1
1
Buy
42
41
44
47
41
Hold
16
15
17
17
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
58
56
61
65
55
In the current month, RGO has received 42 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. RGO average Analyst price target in the past 3 months is 712.05.
Each month's total comprises the sum of three months' worth of ratings.

RGO Financial Forecast

RGO Earnings Forecast

Next quarter’s earnings estimate for RGO is €9.42 with a range of €7.18 to €11.50. The previous quarter’s EPS was €8.22. RGO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RGO has Performed in-line its overall industry.
Next quarter’s earnings estimate for RGO is €9.42 with a range of €7.18 to €11.50. The previous quarter’s EPS was €8.22. RGO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RGO has Performed in-line its overall industry.

RGO Sales Forecast

Next quarter’s sales forecast for RGO is €3.32B with a range of €3.08B to €3.63B. The previous quarter’s sales results were €3.13B. RGO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RGO has Performed in-line its overall industry.
Next quarter’s sales forecast for RGO is €3.32B with a range of €3.08B to €3.63B. The previous quarter’s sales results were €3.13B. RGO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RGO has Performed in-line its overall industry.

RGO Stock Forecast FAQ

What is DE:RGO’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 712.05.
    What is DE:RGO’s upside potential, based on the analysts’ average price target?
    Regeneron Pharmaceuticals has 12.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Regeneron Pharmaceuticals a Buy, Sell or Hold?
          Regeneron Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Regeneron Pharmaceuticals’s share price target?
            The average share price target for Regeneron Pharmaceuticals is 712.05. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €856.79 ,and the lowest forecast is €551.96. The average share price target represents 12.35% Increase from the current price of €633.8.
              What do analysts say about Regeneron Pharmaceuticals?
              Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Regeneron Pharmaceuticals?
                To buy shares of DE:RGO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.